Ingrid Mayer discusses findings from the ECOG-ACRIN EA1131 trial showing no benefit of postoperative platinum-based chemotherapy versus capecitabine in patients with triple-negative breast cancer who have residual disease following neoadjuvant chemotherapy (4:01).
View more on Medicine Matters oncology: [ Ссылка ]
Ещё видео!